GlassScriptPhysician profile
Lori K Bourne
NPI 1841449766
$4,248.41
in general payments reported to CMS, 2019-2025
40 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $798 · 2022: $843 · 2023: $442 · 2024: $1,164 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.14 |
| Education | $117.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.86 | 2021-2025 | |
| Biogen, INC. | $402.16 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $320.02 | 2023-2025 | Mavenclad |
| Lilly USA, LLC | $225.27 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Livanova USA, INC. | $220.35 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $200.67 | 2021-2025 | Briviact |
| Eisai INC. | $188.37 | 2023-2025 | |
| Tanabe Pharma America, INC. | $171.77 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $162.85 | 2021-2024 | Nourianz |
| Sk Life Science, INC. | $157.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $156.21 | 2021-2025 | |
| Celgene Corporation | $151.12 | 2021-2024 | Zeposia |
| Pfizer INC. | $139.22 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $126.52 | 2021-2025 | Austedo Xr |
| Janssen Biotech, INC. | $113.46 | 2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Bourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.